Prager D - Search Results

1

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.

Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS. Delioukina ML, et al. Among authors: prager d. Cancer. 2002 Apr 15;94(8):2174-9. doi: 10.1002/cncr.10432. Cancer. 2002. PMID: 12001114 Free article. Clinical Trial.

2

A phase II trial of irinotecan in hormone-refractory prostate cancer.

Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. Reese DM, et al. Among authors: prager d. Invest New Drugs. 1998-1999;16(4):353-9. doi: 10.1023/a:1006120910380. Invest New Drugs. 1998. PMID: 10426671 Clinical Trial.

3

A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.

Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, Freeman DJ, Johnson CW, Krishnan K, Johnson D. Crawford J, et al. Among authors: prager d. J Thorac Oncol. 2013 Dec;8(12):1510-8. doi: 10.1097/JTO.0b013e3182a7d1da. J Thorac Oncol. 2013. PMID: 24389433 Free article. Clinical Trial.

4

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK. Socinski MA, et al. Among authors: prager d. J Clin Oncol. 2006 Oct 20;24(30):4840-7. doi: 10.1200/JCO.2006.07.7016. J Clin Oncol. 2006. PMID: 17050869 Clinical Trial.

5

Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB.

Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Pei L, et al. Among authors: prager d. Cancer Res. 1995 Apr 15;55(8):1613-6. Cancer Res. 1995. PMID: 7712461

6

High levels of AP-2-binding activity in cell lines infected with human T-cell leukemia virus type I: possible enhancement of AP-2 binding by human T-cell leukemia virus type I tax.

Mori N, Prager D. Mori N, et al. Among authors: prager d. Cancer Res. 1996 Feb 15;56(4):779-82. Cancer Res. 1996. PMID: 8631013

7

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. Herbst RS, et al. Among authors: prager d. J Clin Oncol. 2005 Sep 1;23(25):5892-9. doi: 10.1200/JCO.2005.02.840. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043829 Clinical Trial.

8

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Heymach JV, et al. Among authors: prager d. J Clin Oncol. 2007 Sep 20;25(27):4270-7. doi: 10.1200/JCO.2006.10.5122. J Clin Oncol. 2007. PMID: 17878479 Clinical Trial.

9

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.

Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM Jr, Novotny PJ, Loprinzi CL. Steensma DP, et al. Among authors: prager dj. J Clin Oncol. 2011 Jan 1;29(1):97-105. doi: 10.1200/JCO.2010.30.3644. Epub 2010 Nov 22. J Clin Oncol. 2011. PMID: 21098317 Free PMC article. Clinical Trial.

10

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Kris MG, et al. Among authors: prager d. JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149. JAMA. 2003. PMID: 14570950 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page